Encephalomyelitis-Influenza-West Nile virus vaccine

Overview

  • Protects against EIV, EEE, WEE, tetanus and West Nile virus in 1 mL dose
  • At least six-month duration of immunity against equine influenza (Ohio/03)
  • Ohio/03 (Florida Clade 1), Kentucky/95, and Richmond/07 (Florida Clade 2) equine influenza strains as recommended by the Expert Surveillance Panel on Equine Influenza
  • At least 12-month WNV DOI
  • Contains equine origin 2005 West Nile virus isolate (E159®)
  • Incorporates the Carbimmune® adjuvant formulation to optimize vaccine performance and minimize reactions
  • Unique Ultrafil® Purification Technology purification process and adjuvant formulation minimizes non-relevant protein presented to the immune system
  • Available in single dose pre-filled syringes or color-coded 10 dose vials
  • Safe for use in horses as young as 4 months of age, including pregnant broodmares

Features

  • Includes Ohio/03 (Florida Clade 1), Kentucky/95, and Richmond/07 (Florida Clade 2) equine influenza strains as recommended by the Expert Surveillance Panel on Equine Influenza
  • Contains equine origin 2005 West Nile virus isolate (E159®)
  • Incorporates the Carbimmune® adjuvant formulation
  • Ultrafil® purification technology
  • At least 6 months duration of immunity against equine influenza (Ohio/03)
  • Safe for use in horses as young as 4 months of age, including pregnant mares

Benefits

  • Contains relevant influenza viruses, including Florida Clade 1 and Florida Clade 2 strains
  • Protection against WNV
  • Dual phase system delivers both rapid and long-lasting immunity
  • Safe, high-quality vaccines

Shake well before use.  Using aseptic technique, inoculate horses intramuscularly with a 1 mL dose. Administer a second 1 mL dose intramuscularly in 3-4 weeks using a different injection site. Revaccinate annually and prior to anticipated exposure with a single 1 mL intramuscular dose.

This product has been tested under laboratory conditions and shown to meet all Federal standards for safety and efficacy in normal, healthy, immunocompetent animals.  This level of performance may be affected by conditions such as stress, weather, nutrition, disease, parasitism, other treatments, individual idiosyncrasies, or impaired immunological competency.  These factors should be considered by the user when evaluating product performance or freedom from reactions.

Do not vaccinate within 21 days before slaughter.
Antidote: Epinephrine.

Product Resources

Technical Assistance

  • Boehringer Ingelheim Vetmedica, Inc.

    Equine Division

    3902 Gene Field Road
    St. Joseph, Missouri 64506

    • Phone 866-638-2226
    • Fax 816-676-4326